Highland Capital Management (Tennessee)’s Ionis Pharmaceuticals IONS Stock Holding History

Highland Capital Management (Tennessee)’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,819	Closed	-$963K	–	439
2026 Q1	$963K	Buy	+12,819	New	+$1.01M	0.05%	241
2023 Q2	–	Sell	-37,598	Closed	-$1.34M	–	334
2023 Q1	$1.34M	Sell	37,598 -2,712	-7%	-$102K	0.1%	172
2022 Q4	$1.52M	Buy	40,310 +1,437	+4%	+$60.4K	0.11%	187
2022 Q3	$1.72M	Sell	38,873 -286	-0.7%	-$12.1K	0.13%	164
2022 Q2	$1.45M	Buy	+39,159	New	+$1.48M	0.1%	196
2019 Q4	–	Sell	-3,440	Closed	-$206K	–	319
2019 Q3	$206K	Buy	3,440 +240	+8%	+$15.6K	0.02%	297
2019 Q2	$206K	Hold	3,200	–	–	0.02%	291
2019 Q1	$260K	Buy	+3,200	New	+$206K	0.02%	292
2015 Q3	–	Sell	-500	Closed	-$29K	–	675
2015 Q2	$29K	Buy	+500	New	+$31.8K	﹤0.01%	430

Other funds holding IONS

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Highland Capital Management (Tennessee)'s IONS Position: Q2 2026 in Review

Highland Capital Management (Tennessee) sold out of Ionis Pharmaceuticals (IONS) in Q2 2026, closing a stake of 12,819 shares — an estimated $963K sold.

Highland Capital Management (Tennessee) first reported a position in IONS in Q2 2015 and held it in 9 quarters. The position peaked at $1.72M in Q3 2022. 170 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Highland Capital Management (Tennessee) reported no remaining Ionis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Highland Capital Management (Tennessee) sold 12,819 Ionis Pharmaceuticals shares in Q2 2026, an estimated $963K.
Highland Capital Management (Tennessee) first reported a position in Ionis Pharmaceuticals in Q2 2015 and held it in 9 quarters.
Highland Capital Management (Tennessee)'s Ionis Pharmaceuticals position peaked at $1.72M in Q3 2022.
170 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Highland Capital Management (Tennessee)'s 13F filing for Q2 2026, filed 21 Jul 2026.